Table 1:

Food and Drug Administration (FDA) approved histone deacetylase inhibitors.

Inhibitor	Class	FDA treatment approval	target	FDA approval Date	Terminal half life T1/2 (h)	Ref.
Vorinostat/SAHA	hydroxamic acid	T cell lymphoma	pan	2006	1.05-1.44	89.90
Belinostat	hydroxamic acid	T cell lymphoma	pan	2015	0.45-2.9	91,92
Panobinostat	hydroxamic acid	multiple myeloma	pan	2015	13-29.3	50
Romidepsin	cyclic tetrapeptide	cutaneous T cell lymphoma	I	2009	1.1-8.1	93,94
Valproic acid	short chain fatty acids	seizures	I, IIA	1978*	10-20	95
Phenylbutyric acid	short chain fatty acids	hyperammonaemia	I,II	1996*	<1	96

Footnote: Ref. - reference